ImpediMed Ltd
ASX:IPD
ImpediMed Ltd
Gross Profit
ImpediMed Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ImpediMed Ltd
ASX:IPD
|
Gross Profit
AU$10.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
21%
|
CAGR 10-Years
13%
|
|
|
Somnomed Ltd
ASX:SOM
|
Gross Profit
AU$60.2m
|
CAGR 3-Years
14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
13%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Gross Profit
AU$17.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
8%
|
|
|
Cochlear Ltd
ASX:COH
|
Gross Profit
AU$1.7B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Gross Profit
AU$632.8k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
36%
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ImpediMed Ltd
Glance View
ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.
See Also
What is ImpediMed Ltd's Gross Profit?
Gross Profit
10.1m
AUD
Based on the financial report for Dec 31, 2024, ImpediMed Ltd's Gross Profit amounts to 10.1m AUD.
What is ImpediMed Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
13%
Over the last year, the Gross Profit growth was 11%. The average annual Gross Profit growth rates for ImpediMed Ltd have been 6% over the past three years , 21% over the past five years , and 13% over the past ten years .
You don't have any saved screeners yet